Combination of | |
---|---|
Aztreonam | β-lactam antibiotic |
Avibactam | β-Lactamase inhibitor |
Clinical data | |
Trade names | Emblaveo |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections. [2] [3] [4] [5] Drug resistance to the combination has been reported. [6]
The combination was approved for medical use in the European Union in April 2024. [2] [7]
Aztreonam/avibactam is indicated for the treatment of complicated intra-abdominal infection; hospital-acquired pneumonia, including ventilator-associated pneumonia; or complicated urinary tract infection, including pyelonephritis. [2] It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. [2]
In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emblaveo, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in people with limited treatment options. [1] [8] The applicant for this medicinal product is Pfizer Europe MA EEIG. [1] The combination was approved for medical use in the European Union in April 2024. [2]
Combination of | |
---|---|
Aztreonam | β-lactam antibiotic |
Avibactam | β-Lactamase inhibitor |
Clinical data | |
Trade names | Emblaveo |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections. [2] [3] [4] [5] Drug resistance to the combination has been reported. [6]
The combination was approved for medical use in the European Union in April 2024. [2] [7]
Aztreonam/avibactam is indicated for the treatment of complicated intra-abdominal infection; hospital-acquired pneumonia, including ventilator-associated pneumonia; or complicated urinary tract infection, including pyelonephritis. [2] It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. [2]
In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emblaveo, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in people with limited treatment options. [1] [8] The applicant for this medicinal product is Pfizer Europe MA EEIG. [1] The combination was approved for medical use in the European Union in April 2024. [2]